Beyond the Scale

GLP-1 medication can do more than just change a number on a scale. The strongest evidence so far points to potential benefits in cardiovascular health, glucose regulation, body composition, physical function, sleep apnea, and quality of life. The strength of the evidence and extent of these benefits depends on the specific medication and population studied.

Weight is one visible outcome of treatment. However, it is not the only outcome that matters. A person may notice improvements in sleep, blood pressure, mobility, and ease of everyday activities. Other benefits may appear first through changes in laboratory results or cardiovascular risk, even before noticeable differences are felt in daily life.

The phrase “beyond the scale” should not be taken to mean that every person will experience every benefit. Rather, it means that GLP-1 treatment is being studied for a wider set of health outcomes than body weight alone.

Cardiovascular health

One of the clearest examples of cardiovascular benefit from GLP-1 treatment comes from the SELECT trial. This study enrolled adults age 45 or older with established cardiovascular disease, a body-mass index of at least 27, and no history of diabetes. After a mean follow-up of 39.8 months, it was found that weekly semaglutide 2.4 mg reduced the combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke when compared with placebo. The hazard ratio was 0.80, which corresponds to a relative risk reduction of about 20% in this study population. [1]

This is an important result because it describes a clinical outcome, not just a change in body composition. It also needs to be read precisely. SELECT studied a particular group of adults with established cardiovascular disease who did not have diabetes. Its result should not be treated as a promise that every person taking a GLP-1 medicine will have the same reduction in cardiovascular events.

Blood sugar and cardiometabolic health

GLP-1 medicines can improve blood sugar regulation by a variety of pathways, including increasing glucose-dependent insulin release, reducing inappropriate glucagon signaling, and slowing gastric emptying. The clinical effect varies by medication, dose, and the person’s underlying metabolic health.

In an analysis of the SELECT trial, the cardiovascular benefit of semaglutide was found to be similar in people who started with different HbA1c levels and in people whose HbA1c changed by different amounts during the trial. In other words, the reduction in cardiovascular events could not be explained only by lowering blood sugar. HbA1c still matters, especially for people with diabetes or prediabetes, but the findings suggest that other effects of treatment may also contribute to cardiovascular benefit. [2]

Semaglutide studies and reviews have also reported improvements in several cardiometabolic risk factors, including blood pressure, triglycerides, and atherogenic lipid measures. These changes may contribute to a healthier overall risk profile. They are not the same as preventing a heart attack or stroke, but they help explain why the effects of treatment can extend beyond body weight. [3]

Physical function and quality of life

Weight loss can offer benefits beyond changes in body size, including making movement and everyday activities feel easier. In patient-reported analyses from the STEP 1 through STEP 4 trials, semaglutide 2.4 mg was associated with improvements in physical functioning, weight related quality of life, and overall health-related quality of life.

In the STEP 1 trial, clinically meaningful improvements in physical function were more common among participants treated with semaglutide than those treated with placebo. On the IWQOL-Lite-CT physical-function domain, 51.8% of the semaglutide group reported meaningful improvement, compared with 28.3% of the placebo group. On the SF-36v2 physical-functioning scale, the respective proportions were 39.8% and 24.1%. [4]

These findings are encouraging because they reflect patients’ perceptions of their physical abilities and quality of life, rather than just weight change alone. However, the findings were primarily based on self-reported questionnaires, and participants also received lifestyle interventions as part of the trial. In this context, a better physical-function score does not automatically prove that muscle strength increased or that everyday activities will become easier for everyone.

Fat mass, visceral fat, and lean mass

Body-composition research offers a more detailed picture of how GLP-1 treatment affects the body. In a DEXA substudy of the STEP 1 trial, participants receiving semaglutide lost 15.0% of their body weight over 68 weeks. Total fat mass fell by 19.3%, and regional visceral fat mass fell by 27.4%. Visceral fat is metabolically active fat stored around internal organs and is associated with cardiometabolic risk. [5]

Total lean body mass also fell by 9.7% in this substudy, although lean mass as a proportion of body weight rose by three percentage points. The proportion increased because fat mass fell more than lean mass, so lean tissue made up a larger share of a smaller total body weight. This does not mean that lean tissue increased. Importantly, DEXA-derived lean mass includes more than skeletal muscle; it also encompasses water, organs, connective tissue, and other nonfat tissues. Therefore, changes in measured lean mass do not directly indicate how much contractile muscle was lost or whether muscle strength or physical function declined.

A small secondary analysis from the SLIM LIVER study offers a related example. Fifty-one people with HIV and metabolic dysfunction-associated steatotic liver disease received semaglutide titrated to 1 mg weekly for 24 weeks. Psoas muscle volume fell by 9.3%, while physical function tests including chair-rise time and gait speed did not change significantly. In this small study, measured physical function appeared to be maintained despite a reduction in the volume of one muscle group. [6]

These studies do not show that muscle loss is harmless, inevitable, or clinically unimportant. They show that body composition and physical function are related but different outcomes. A reduction in fat mass may be accompanied by better mobility or quality of life, while a reduction in lean mass still deserves careful interpretation.

The strongest recent drug evidence for obstructive sleep apnea comes from tirzepatide, a dual GIP and GLP-1 receptor agonist. In the SURMOUNT-OSA phase 3 trials, adults with moderate-to-severe obstructive sleep apnea and obesity received tirzepatide or placebo for 52 weeks. Tirzepatide reduced the apnea-hypopnea index, improved sleep-related patient-reported outcomes, and lowered systolic blood pressure. [7]

These findings suggest that treatment may improve more than daytime weight-related symptoms. Better control of sleep apnea can affect sleep quality, daytime alertness, blood pressure, and overall quality of life. The results should not be transferred automatically to semaglutide or to every person with sleep apnea. The trials excluded several groups, including people with type 1 or type 2 diabetes and people with central or mixed sleep apnea.

Taken together, these studies suggest that GLP-1 medicines may influence several dimensions of health beyond body weight. The evidence includes fewer major cardiovascular events in the SELECT population, improved patient-reported physical function and quality of life in the STEP trials, changes in fat and visceral fat in body-composition studies, and improvements in sleep apnea outcomes in the SURMOUNT-OSA phase 3 trials. These are encouraging findings, but they do not mean that patients will be affected in the same way.

Additionally, potential benefits from GLP-1 therapy are not limited to a lower number on your scale. Progress may mean walking farther, climbing stairs with less effort, sleeping more soundly, having a safer glucose or lipid profile, or feeling more able to participate in ordinary life. At the same time, gastrointestinal symptoms, dehydration, inadequate nutrition, or loss of physical function can offset the benefits of weight loss. Therefore, it is important to look at the evidence holistically when interpreting the potential benefits of treatment.

Medical-education disclaimer: This article is for general education and journal-club discussion, not individualized medical advice. GLP-1 medicines have important contraindications, interactions, and adverse effects. Decisions about treatment should be made with a qualified clinician who knows the patient’s medical history.

Beyond the Scale

Cardiovascular health

Blood sugar and cardiometabolic health

Physical function and quality of life

Fat mass, visceral fat, and lean mass

Sleep apnea and sleep-related health

Beyond the scale

References